Pfizer (PFE) PT Raised to $28 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $30.76 +2.53%
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
RBC Capital analyst Trung Huynh raised the price target on Pfizer (NYSE: PFE) to $28.00 (from $25.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Pfizer (PFE) PT Lowered to $26 at Morgan Stanley
- Marriott International (MAR) PT Lowered to $141 at Jefferies
- Datadog (DDOG) PT Lowered to $230 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
